유럽의 유전체형 분석 시장(-2031년)

The Europe genotyping market was valued at US$ 8,729.90 million in 2023 and is expected to reach US$ 43,883.43 million by 2031; it is estimated to record a CAGR of 22.4% from 2023 to 2031.

Technological Advancements and Rising R&D Investments in Biotechnology and Pharmaceutical Industry Drives Europe Genotyping Market

Genotyping market players are focusing on increasing their investments in projects aimed at advancements in biotechnology to come up with better alternatives to conventional techniques.

In January 2024, Thermo Fisher Scientific launched Axiom PangenomiX Array, offering optimal genetic coverage for pharmacogenomic research and population-scale disease studies. This array is currently the only research solution that can run four assays in one test: SNP genotyping, complete genome copies number variant detection, fixed copy number discovery, and blood and HLA typing. In September 2023, Bio-Rad launched new PTC Tempo 48/48 and PTC Tempo 384 thermal cyclers for sequencing, cloning, and genotyping. The PTC Tempo thermal cyclers are built with an intuitive user interface and flexible connectivity features to streamline protocol management, along with monitoring capabilities on the cloud platform. In January 2023, Qiagen acquired Verogen, a company that uses next-generation sequencing (NGS) techniques to drive the future of forensic investigation and human identification (HID). QIAGEN and Verogen together are expected to create opportunities to help researchers advance forensic science, thereby aiding accurate suspect identification, finding missing persons, and exonerating innocent individuals. In June 2022, NRGene launched Soy SNPro, a product covered under predesigned SNP sets for genotyping (DNA tests) of various crops. SNPro is an off-the-shelf complete genotyping solution that combines low-density genotyping with high-density imputation. In May 2022, NEOGEN Corporation and Gencove announced the launch of InfiniSEEK, an innovative and cost-effective solution for addressing difficulties involved in whole-genome sequencing and targeted SNP analyses. Such technological breakthroughs have the potential to enable miniaturization, automation, and cost reduction. They can also aid in operational flexibility and multiparameter testing. All these benefits add to the uses and convenience of DNA sequencing, allowing clinicians to concentrate on higher-level decisions such as selecting and prioritizing therapeutic targets through various genotyping studies. Further, technological advancements in DNA sequencing, such as NGS, have enabled speedy, accurate sequencing, allowing for great productivity. Thus, the growing research and development activities, along with increasing government funding for genome-based projects, contribute to the genotyping market progress.

Europe Genotyping Market Overview

The Europe genotyping market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds the second-largest share of the global genotyping market and is expected to register a notable CAGR during the forecast period. Factors such as technological advancements, reducing prices of DNA sequencing procedures, increasing incidence of genetic diseases, and rising awareness of personalized medicine are among the factors aiding the growth of the Europe genotyping market .

Europe Genotyping Market Revenue and Forecast to 2031 (US$ Million)

Europe Genotyping Market Segmentation

The Europe genotyping market is categorized into product type, technology, application, end user, and country.

Based on product type, the Europe genotyping market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held the largest market share in 2023.

By technology, the Europe genotyping market is segmented into microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption / MALDI-TOF, and other technologies. The polymerase chain reaction (PCR) segment held the largest market share in 2023.

Based on application, the Europe genotyping market is bifurcated into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. The diagnostics and personalized medicine segment held the largest market share in 2023.

In terms of end user, the Europe genotyping market is bifurcated into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Europe genotyping market is segmented into the UK, Germany, France, Spain, Italy, and the Rest of Europe. Germany dominated the Europe genotyping market share in 2023.

Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, EUROFINS GENOMICS, Thermo Fisher Scientific Inc, BioTek Instruments Inc, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA. are some of the leading companies operating in the Europe genotyping market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Europe Genotyping Market Landscape

• 4.1 Overview
• 4.2 Global Market Share Analysis
  • 4.2.1 Global Market Share (%) of Leading Players for NGS Library Preparation
  • 4.2.2 Global Market Share (%) of Leading Player for Genotyping
  • 4.2.3 Global Market Share (%) of Leading Player for Gene Expression

5. Europe Genotyping Market - Key Market Dynamics

• 5.1 Market Drivers:
  • 5.1.1 Use in Diagnosis of Genetic and Rare Diseases
  • 5.1.2 Technological Advancements and Rising R&D Investments in Biotechnology and Pharmaceutical Industry
• 5.2 Market Restraints
  • 5.2.1 High Cost of Equipment and Shortage of Skilled Professionals
• 5.3 Market Opportunities
  • 5.3.1 Expanding Range of Applications
• 5.4 Future Trends
  • 5.4.1 Increasing Popularity of Personalized Medicine
• 5.5 Impact of Drivers and Restraints:

6. Genotyping Market - Europe Analysis

• 6.1 Genotyping Market Revenue (US$ Million), 2021-2031

7. Europe Genotyping Market Analysis - by Product Type

• 7.1 Instruments
  • 7.1.1 Overview
  • 7.1.2 Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 7.2 Reagents and Kits
  • 7.2.1 Overview
  • 7.2.2 Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 7.3 Bioinformatics
  • 7.3.1 Overview
  • 7.3.2 Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 7.4 Genotyping Services
  • 7.4.1 Overview
  • 7.4.2 Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Genotyping Market Analysis - by Technology

• 8.1 Microarray
  • 8.1.1 Overview
  • 8.1.2 Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 8.2 Capillary Electrophoresis
  • 8.2.1 Overview
  • 8.2.2 Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 8.3 Sequencing
  • 8.3.1 Overview
  • 8.3.2 Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 8.4 Polymerase Chain Reaction (PCR)
  • 8.4.1 Overview
  • 8.4.2 Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 8.5 Matrix-Assisted Laser Desorption / MALDI-TOF
  • 8.5.1 Overview
  • 8.5.2 Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 8.6 Other Technologies
  • 8.6.1 Overview
  • 8.6.2 Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Genotyping Market Analysis - by Application

• 9.1 Pharmacogenomics
  • 9.1.1 Overview
  • 9.1.2 Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 9.2 Diagnostics and Personalized Medicine
  • 9.2.1 Overview
  • 9.2.2 Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 9.3 Animal Genetics
  • 9.3.1 Overview
  • 9.3.2 Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 9.4 Agricultural Biotechnology
  • 9.4.1 Overview
  • 9.4.2 Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 9.5 Other Applications
  • 9.5.1 Overview
  • 9.5.2 Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Genotyping Market Analysis - by End-user

• 10.1 Pharmaceutical and Biopharmaceutical Companies
  • 10.1.1 Overview
  • 10.1.2 Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 10.2 Diagnostic and Research Laboratories
  • 10.2.1 Overview
  • 10.2.2 Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 10.3 Academic Institutes
  • 10.3.1 Overview
  • 10.3.2 Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
• 10.4 Other End Users
  • 10.4.1 Overview
  • 10.4.2 Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

11. Europe Genotyping Market - Country Analysis

• 11.1 Europe Genotyping Market Overview
  • 11.1.1 Europe: Genotyping Market - Revenue and Forecast Analysis - by Country
    • 11.1.1.1 United Kingdom: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.1.1.1 United Kingdom: Genotyping Market Breakdown, by Product Type
      • 11.1.1.1.2 United Kingdom: Genotyping Market Breakdown, by Technology
      • 11.1.1.1.3 United Kingdom: Genotyping Market Breakdown, by Application
      • 11.1.1.1.4 United Kingdom: Genotyping Market Breakdown, by End-user
    • 11.1.1.2 Germany: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.1.2.1 Germany: Genotyping Market Breakdown, by Product Type
      • 11.1.1.2.2 Germany: Genotyping Market Breakdown, by Technology
      • 11.1.1.2.3 Germany: Genotyping Market Breakdown, by Application
      • 11.1.1.2.4 Germany: Genotyping Market Breakdown, by End-user
    • 11.1.1.3 France: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.1.3.1 France: Genotyping Market Breakdown, by Product Type
      • 11.1.1.3.2 France: Genotyping Market Breakdown, by Technology
      • 11.1.1.3.3 France: Genotyping Market Breakdown, by Application
      • 11.1.1.3.4 France: Genotyping Market Breakdown, by End-user
    • 11.1.1.4 Spain: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.1.4.1 Spain: Genotyping Market Breakdown, by Product Type
      • 11.1.1.4.2 Spain: Genotyping Market Breakdown, by Technology
      • 11.1.1.4.3 Spain: Genotyping Market Breakdown, by Application
      • 11.1.1.4.4 Spain: Genotyping Market Breakdown, by End-user
    • 11.1.1.5 Italy: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.1.5.1 Italy: Genotyping Market Breakdown, by Product Type
      • 11.1.1.5.2 Italy: Genotyping Market Breakdown, by Technology
      • 11.1.1.5.3 Italy: Genotyping Market Breakdown, by Application
      • 11.1.1.5.4 Italy: Genotyping Market Breakdown, by End-user
    • 11.1.1.6 Rest of Europe: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.1.6.1 Rest of Europe: Genotyping Market Breakdown, by Product Type
      • 11.1.1.6.2 Rest of Europe: Genotyping Market Breakdown, by Technology
      • 11.1.1.6.3 Rest of Europe: Genotyping Market Breakdown, by Application
      • 11.1.1.6.4 Rest of Europe: Genotyping Market Breakdown, by End-user

12. Industry Landscape

• 12.1 Overview
• 12.2 Growth Strategies in Genotyping Market
• 12.3 Organic Growth Strategies
  • 12.3.1 Overview
• 12.4 Inorganic Growth Strategies
  • 12.4.1 Overview

13. Company Profiles

• 13.1 Hoffmann-La Roche Ltd
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
• 13.2 QIAGEN NV
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
• 13.3 Merck KGaA
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
• 13.4 EUROFINS GENOMICS
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
• 13.5 Thermo Fisher Scientific Inc
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
• 13.6 BioTek Instruments, Inc.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
• 13.7 Illumina Inc
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
• 13.8 Danaher Corp
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
• 13.9 Bio-Rad Laboratories Inc
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
• 13.10 GE HealthCare Technologies Inc
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments
• 13.11 Standard BioTools Inc
  • 13.11.1 Key Facts
  • 13.11.2 Business Description
  • 13.11.3 Products and Services
  • 13.11.4 Financial Overview
  • 13.11.5 SWOT Analysis
  • 13.11.6 Key Developments
• 13.12 Laboratory Corp of America Holdings
  • 13.12.1 Key Facts
  • 13.12.2 Business Description
  • 13.12.3 Products and Services
  • 13.12.4 Financial Overview
  • 13.12.5 SWOT Analysis
  • 13.12.6 Key Developments
• 13.13 Beckman Coulter Inc
  • 13.13.1 Key Facts
  • 13.13.2 Business Description
  • 13.13.3 Products and Services
  • 13.13.4 Financial Overview
  • 13.13.5 SWOT Analysis
  • 13.13.6 Key Developments
• 13.14 BGI
  • 13.14.1 Key Facts
  • 13.14.2 Business Description
  • 13.14.3 Products and Services
  • 13.14.4 Financial Overview
  • 13.14.5 SWOT Analysis
  • 13.14.6 Key Developments
• 13.15 Takara Bio Inc
  • 13.15.1 Key Facts
  • 13.15.2 Business Description
  • 13.15.3 Products and Services
  • 13.15.4 Financial Overview
  • 13.15.5 SWOT Analysis
  • 13.15.6 Key Developments
• 13.16 DiaSorin SpA
  • 13.16.1 Key Facts
  • 13.16.2 Business Description
  • 13.16.3 Products and Services
  • 13.16.4 Financial Overview
  • 13.16.5 SWOT Analysis
  • 13.16.6 Key Developments

14. Appendix

• 14.1 About Us
• 14.2 Glossary of Terms